An automated 24-hour CAR-T manufacturing process

As the cell therapy field progresses, manufacturing challenges like patient safety, cost, automation, closed operation, and scalability must be addressed with improved capabilities and workflows. Leveraging new cell therapy technologies and tools to develop innovative end-to-end workflows can enable more cost-effective cell therapy processes and workflows. This article presents an automated and shortened lentiviral-based CAR-T workflow using the Gibco^TM  CTS^TM  Detachable Dynabeads^TM  CD3/CD28 magnetic beads, Gibco^TM CTS^TM Detachable Dynabeads^TM  Release Buffer, and Gibco^TM  CTS^TM   DynaCellect^TM  Magnetic Separation System.

Please enter your email to access content Read now